(Iso)Flav(an)ones, chalcones, catechins, and theaflavins as anticarcinogens: Mechanisms, anti-multidrug resistance and QSAR studies

Current Medicinal Chemistry

Volumn 19, Issue 25, 2012, Pages 4324-4347

  Mercader, Andrew G ^a   Pomilio, Alicia B ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

(iso)flavones; Anticarcinogens; Catechins; Chalcones; Flavanones; Flavonoids; Flavonoids chemotherapy; Flavonoids TRAIL; QSAR; Theaflavins; TRAIL

Indexed keywords

5,6 DIMETHOXY 7 HYDROXYFLAVONE; 5,6,4' TRIHYDROXY 7,3' DIMETHOXYFLAVONE; 5,7 DIHYDROXY 3,6 DIMETHOXYFLAVONE; AMENTOFLAVONE; ANTINEOPLASTIC AGENT; APIGENIN; BIOCHANIN A; CATECHIN; CHALCONE DERIVATIVE; CHRYSIN; DAIDZEIN; FLAVANONE; GALANGIN; GENISTEIN; HISPIDULIN; ISOFLAVONE DERIVATIVE; ISORHAMNETIN 3 ROBINOBIOSIDE; KAEMPFEROL; KAEMPFEROL 3 O ROBINOBIOSIDE; LUTEOLIN; MYRICETIN; NICOTIFLORIN; NOBILETIN; QUERCETIN; QUERCETIN 3 O ROBINOBIOSIDE; ROBININ; TANGERETIN; TAXIFOLIN; THEAFLAVIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CHEMOPROPHYLAXIS; DNA REPLICATION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; BIFLAVONOIDS; CATECHIN; CHALCONES; HUMANS; ISOFLAVONES; NEOPLASMS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866676019     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802884277     Document Type: Article

References (261)

1. Middleton Jr., E.; Kandaswami, C.; Theoharides, T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev., 2000, 52, 673-751.
2. Mercader, A.G.; Pomilio, A.B. QSAR study of flavonoids and biflavonoids as influenza H1N1 virus neuraminidase inhibitors. Eur. J. Med. Chem., 2010, 45, 1724-1730.
3. Mercader, A.G.; Pomilio, A.B. 2D-and 3D-QSAR studies of flavonoids, biflavones and chalcones: antiviral, antibacterial, antifungal, and antimycobacterial activities. Anti-Infect. Agents Med. Chem., 2012, 10, 41-54.
4. Mercader, A.; Pomilio, A.B. Biflavonoids: Occurrence, Structural Features and Bioactivity. Series: Chemistry Research and Applications. Nova Science Publishers: New York, 2012. ISBN: 978-1-62100-354-0
5. Buschi, C.A.; Pomilio, A.B.; Gros, E.G. A new flavone from Gomphrena martiana. Phytochemistry, 1979, 18, 1249-1250.
6. Buschi, C.A.; Pomilio, A.B.; Gros, E.G. New methylated flavones from Gomphrena martiana. Phytochemistry, 1980, 19, 903-906.
7. Buschi, C.A.; Pomilio, A.B.; Gros, E.G. 5, 6, 7-Trisubstituted flavones from Gomphrena martiana. Phytochemistry, 1981, 20, 1178-1180.
8. Buschi, C.A.; Pomilio, A.B. Isorhamnetin 3-O-robinobioside from Gomphrena martiana. J. Nat. Prod., 1982, 45, 557-559.
9. Pomilio, A.B.; Buschi, C.A.; Rutty Solá, G.A.; Rumi, L.S. Antitumor screening of Gomphrena species. Fitoterapia, 1991, 62, 511-514.
10. Pomilio, A.B.; Rutty Solá, G.A.; Mayer, A.M.; Rumi, L.S. Antitumor and cytotoxic screen of 5, 6, 7-trisubstituted flavones from Gomphrena martiana. J. Ethnopharmacol., 1994, 44, 25-33.
11. Pomilio, A.B.; Buschi, C.A.; Tomes, C.N.; Viale A.A. Antimicrobial constituents of Gomphrena martiana and Gomphrena boliviana. J. Ethnopharmacol., 1992, 36, 155-161.
12. Pomilio, A.B.; Vacchino, M.N.; Vitale, A.A. Antimycobacterial and antitumoral activities of argentine plants belonging to the Amaranthaceae family. In: South American Medicinal Plants as a Potential Source of Bioactive Compounds. Martino, V.S.; Muschietti, L.V., Eds.; Transworld Research Network: Kerala, India, distributed by American Technical Publishers Ltd.: Herts, Hitchin, UK, 2008; Chapter 5, pp. 73-113.
13. Seo, J.M.; Kang, H.M.; Son, K.H.; Kim, J.H.; Lee, C.W.; Kim, H.M.; Chang, S.I.; Kwon, B.M. Antitumor activity of flavones isolated from Artemisia argyi. Planta Med., 2003, 69, 218-222.
14. Brochado, C. de O.; de Almeida, A.P.; Barreto, B.P.; Costa, L.P.; Ribeiro, L.S.; Pereira, R.L. da C.; Gonçalves Koatz, V.L.; Costa, S.S. Flavonol robinobiosides and rutinosides from Alternanthera brasiliana (Amaranthaceae) and their effects on lymphocyte proliferation in vitro. J. Braz. Chem. Soc., 2003, 14, 449-451.
15. Chen, J.J.; Lee, H.H.; Duh, C.Y.; Chen, I.S. Cytotoxic chalcones and flavonoids from the leaves of Muntingia calabura. Planta Med., 2005, 71, 970-973.
16. Itoigawa, M.; Ito, C.; Ju-ichi, M.; Nobukuni, T.; Ichiishi, E.; Tokuda, H.; Nishino, H.; Furukawa, H. Cancer chemopreventive activity of flavanones on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. Cancer Lett., 2002, 176, 25-29.
17. Ye, C.-L.; Liu, J.-W.; Wei, D.-Z.; Lu, Y.-H.; Qian, F. In vitro anti-tumor activity of 2', 4'-dihydroxy-6'-methoxy-3', 5'-dimethylchalcone against six established human cancer cell lines. Pharmacol. Res., 2004, 50, 505-510.
18. Ye, C.-L.; Qian, F.; Wei, D.-Z.; Lu, Y.-H.; Liu, J.-W. Induction of apoptosis in K562 human leukemia cells by 2', 4'-dihydroxy-6'-methoxy-3', 5'-dimethylchalcone. Leukemia Res., 2005, 29, 887-892.
19. Cao, Y.; Tan, N.-H.; Chen, J.-J.; Zeng, G.-Z.; Ma, Y.-B.; Wu, Y.-P.; Yan, H.; Yang, J.; Lu, L.-F.; Wang, Q. Bioactive flavones and biflavones from Selaginella moellendorffii Hieron. Fitoterapia, 2010, 81, 253-258.
20. López-Lázaro, M.; Gálvez, M.; Martín-Cordero, C.; Ayuso, M.J. Cytotoxicity of flavonoids on cancer cell lines. Structure-activity relationship. Studies in Natural Products Chemistry, 2002, 27, 891-932.
21. Li, Y.; Fang, H.; Xu, W. Recent advance in the research of flavonoids as anticancer agents. Mini Rev. Med. Chem. 2007, 7, 663-678.
22. Alonso-Castro, A.J.; Villarreal, M.L.; Salazar-Olivo, L.A.; Gomez-Sanchez, M.; Dominguez, F.; Garcia-Carranca, A. Mexican medicinal plants used for cancer treatment: Pharmacological, phytochemical and ethnobotanical studies. J. Ethnopharmacol., 2011, 133, 945-972.
23. Das, M.; Chaudhuri, T.; Goswami, S.K.; Murmu, N.; Gomes, A.; Mitra, S.; Besra, S.E.; Sur, P.; Vedasiromoni, J.R. Studies with black tea and its constituents on leukemic cells and cell lines. J. Exp. Clin. Cancer Res., 2002, 21, 563-568.
24. Dreger, H.; Lorenz, M.; Kehrer, A.; Baumann, G.; Stangl , K.; Stangl, V. Characteristics of catechin-and theaflavin-mediated cardioprotection. Exp. Biol. Med. (Maywood), 2008, 233, 427-433.
25. Sitheeque, M.A.; Panagoda, G.J.; Yau, J.; Amarakoon, A.M.; Udagama, U.R.; Samaranayake, L.P. Antifungal activity of black tea polyphenols (catechins and theaflavins) against Candida species. Chemotherapy, 2009, 55, 189-196.
26. Yoshino, K.; Yamazaki, K.; Sano, M. Preventive effects of black tea theaflavins against mouse type IV allergy. J. Sci. Food Agric., 2010, 90, 1983-1987.
27. Hosokawa, Y.; Hosokawa, I.; Ozaki, K.; Nakanishi, T.; Nakae, H.; Matsuo, T. Tea polyphenols inhibit IL-6 production in tumor necrosis factor superfamily 14-stimulated human gingival fibroblasts. Mol. Nutr. Food Res., 2010, 54, S151-S158.
28. Hosokawa, Y.; Hosokawa, I.; Ozaki, K.; Nakanishi, T:, Nakae, H.; Matsuo, T. Catechins inhibit CXCL10 production from oncostatin M-stimulated human gingival fibroblasts. J. Nutr. Biochem., 2010, 21, 659-664.
29. Skrzypczak-Jankun, E.; Jankun, J. Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity? Int. J. Mol. Med., 2010, 26, 45-50.
30. Jankun, J.; Skotnicka, M.;Łysiak-Szydłowska, W.; Al-Senaidy, A.; Skrzypczak-Jankun, E. Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea. Int. J. Mol. Med., 2011, 27, 525-529.
31. Babich, H.; Pinsky, S.M.; Muskin, E.T.; Zuckerbraun, H.L. In vitro cytotoxicity of a theaflavin mixture from black tea to malignant, immortalized, and normal cells from the human oral cavity. Toxicol. In Vitro, 2006, 20, 677-688.
32. Kimura, K.; Itakura, Y.; Goto, R.; Tojima, M.; Egawa, N.; Yoshihama, M. Inhibition of 17-hydroxylase/C17, 20-lyase (CYP17) from rat testis by green tea catechins and black tea theaflavins. Biosci. Biotechnol. Biochem., 2007, 71, 2325-2328.
33. Dou, Q.P. Molecular mechanisms of green tea polyphenols. Cancer, 2009, 61, 827-835.
34. Yang, C.S.; Chung, J.Y.; Yang, G.; Chhabra, S.K.; Lee, M.J. Tea and tea polyphenols in cancer prevention. J. Nutr., 2000, 130, 472S-478S.
35. Lin, L.Z.; Chen, P.; Harnly, J.M. New phenolic components and chromatographic profiles of green and fermented teas. J. Agric. Food Chem., 2008, 56, 8130-8140.
36. Yang, C.; Li, D.; Wan, X. Combination of HSCCC and Sephadex LH-20 methods An approach to isolation and purification of the main individual theaflavins from black tea. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 861, 140-144.
37. Wiseman, S.A.; Balentine, D.A.; Frei, B. Antioxidants in tea. Crit. Rev. Food Sci. Nutr., 1997, 37, 705-718.
38. Landau, J.M.; Wang, Z.-Y.; Yang, G.-Y.; Ding, W.; Yang, C.S. Inhibition of spontaneous formation of lung tumors and rhabdomyosarcomas in A/J mice by black and green tea. Carcinogenesis, 1998, 19, 501-507.
39. Yang, G.-Y.; Liao, J.; Kim, K.; Yurkow, E.J.; Yang, C.S. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis, 1998, 19, 611-616.
40. Morse, M.A.; Kresty, L.A.; Steele, V.E.; Kelloff, G.J.; Boone, C.W.; Balentine, D.A.; Harbowy, M.E.; Stoner, G.D. Effects of theaflavins on Nnitrosomethylbenzylamine-induced esophageal tumorigenesis. Nutr. Cancer, 1997, 29, 7-12.
41. Chung, F.-L.; Wang, M.; Rivenson, A.; Iatropoulos, M.J.; Reinhardt, J.C.; Pittman, B.; Ho, C.-T.; Amin, S.G. Inhibition of lung carcinogenesis by black tea in Fischer rats treated with a tobacco-specific carcinogen: caffeine as an important constituent. Cancer Res., 1998, 58, 4096-4101.
42. Rees, J.R.; Stukel, T.A.; Perry, A.E.; Zens, M.S.; Spencer, S.K.; Karagas, M.R. Tea consumption and basal cell and squamous cell skin cancer: results of a case control study. J. Am. Acad. Dermatol., 2007, 56, 781-785.
43. Thomasset, S.C.; Berry, T.P.; Garcea, G.; Marczylo, T.; Steward, W.P.; Gescher, A.J. Dietary polyphenolic phytochemicals-Promising cancer chemopreventive agents in humans? A review of their clinical properties. Int. J. Cancer, 2007, 120, 451-458.
44. Yao, H.; Xu, W.; Shi, X.; Zhang, Z. Dietary flavonoids as cancer prevention agents. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev., 2011, 29, 1-31.
45. Ren, W.; Qiao, Z.; Wang, H.; Zhu, L.; Zhang, L. Flavonoids: promising anticancer agents. Med. Res. Rev. 2003, 23, 519-534.
46. Galati, G.; O'Brien, P.J. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic. Biol. Med., 2004, 37, 287-303.
47. Bode, A.M.; Dong, Z. Molecular and cellular targets. Mol Carcinog. 2006, 45, 422-430.
48. Kumar, G.; Pillare, S.P.; Maru, G.B. Black tea polyphenols-mediated in vivo cellular responses during carcinogenesis. Mini Rev. Med. Chem., 2010, 10, 492-505.
49. Birt, D.F.; Hendrich, S.; Wang, W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Ther. 2001, 90, 157-177.
50. Wang, W.; Goodman, M.T. Antioxidant property of dietary phenolic agents in a human LDL-oxidation ex vivo model: interaction of protein binding activity. Nutr. Res., 1999, 19, 191-202.
51. Cai, Y.; Luo, Q.; Sun, M.; Corke, H. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci., 2004, 74, 2157-2184.
52. Metodiewa, D.; Jaiswal, A.K.; Cenas, N.; Dickancaite, E.; Segura-Aguilar, J. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic. Biol. Med., 1999, 26, 107-116.
53. Galati, G.; Moridani, M.Y.; Chan, T.S.; O'Brien, P.J. Peroxidative metabolism of apigenin and naringenin versus luteolin and quercetin: glutathione oxidation and conjugation. Free Radic. Biol. Med., 2001, 30, 370-382.
54. Moreira, M.R.; Kanashiro, A.; Kabeya, L.M.; Polizello, A.C.M.; Azzolini, A.E.C.S.; Curti, C.; Oliveira, C.A.; do Amaral, A.T.; Lucisano-Valim, Y.M. Neutrophil effector functions triggered by Fc-and/or complement receptors are dependent on B-ring hydroxylation pattern and physicochemical properties of flavonols. Life Sci., 2007, 81, 317-326.
55. Ravikumar, Y.S.; Mahadevan, K.M.; Kumaraswamy, M.N.; Vaidya, V.P.; Manjunatha, H.; Kumar, V.; Satyanarayana, N.D. Antioxidant, cytotoxic and genotoxic evaluation of alcoholic extract of Polyalthia cerasoides (Roxb.) Bedd. Environ. Toxicol. Pharmacol., 2008, 26, 142-146.
56. Yang, Z.; Jie, G.; Dong, F.; Xu, Y.; Watanabe, N.; Tu, Y. Radicalscavenging abilities and antioxidant properties of theaflavins and their gallate esters in H2O2-mediated oxidative damage system in the HPF-1 cells. Toxicol. In Vitro, 2008, 22, 1250-1256.
57. Babich, H.; Gottesman, R.T.; Liebling, E.J.; Schuck, A.G. Theaflavin-3-gallate and theaflavin-3'-gallate, polyphenols in black tea with prooxidant properties. Basic Clin. Pharmacol. Toxicol., 2008; 103, 66-74.
58. Lambert, J.D.; Elias, R.J. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch. Biochem. Biophys., 2010, 501, 65-72.
59. Wang, W.; Higuchi, C.M.; Zhang, R. Individual and combinatory effects of soy isoflavones on the in vitro potentiation of lymphocyte activation. Nutr. Cancer, 1997, 29, 29-34.
60. Zhang, Y.; Song, T.T.; Cunnick, J.E.; Murphy, P.A.; Hendrich, S. Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells in nutritionally relevant concentrations. J. Nutr., 1999, 129, 399-405.
61. Talalay, P.; Fahey, J.W.; Holtzclaw, W.D.; Prestera, T.; Zhang, Y. Chemo-protection against cancer by phase 2 enzyme induction. Toxicol. Lett., 1995, 82-83, 173-179.
62. Kanazawa, K.; Yamashita, T.; Ashida, H.; Danno, G. Antimutagenicity of flavones and flavonols to heterocyclic amines by specific and strong inhibition of the cytochrome P450 1A family. Biosci. Biotechnol. Biochem., 1998, 62, 970-977.
63. Rodgers, E.H.; Grant, M.H. The effect of the flavonoids, quercetin, myricetin and epicatechin on the growth and enzyme activities of MCF7 human breast cancer cells. Chem. Biol. Interact., 1998, 116, 213-228.
64. Wang, W.; Liu, L.Q.; Higuchi, C.M.; Chen, H. Induction of NADPH:quinone reductase by dietary phytoestrogens in colonic Colo205 cells. Biochem. Pharmacol., 1998, 56, 189-195.
65. Premalatha, B.; Sachdanandam, P. Potency of Semecarpus anacardium Linn. nut milk extract against aflatoxin b1-induced hepatocarcinogenesis: reflection on microsomal biotransformation enzymes. Pharmacol. Res., 2000, 42, 161-166.
66. Kim, H.P.; Mani, I.; Iversen, L.; Ziboh, V.A. Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. Prostagl. Leukotr. Essent. Fatty Acids, 1998, 58, 17-24.
67. Banerjee, T.; Van der Vliet, A.; Ziboh, V.A. Downregulation of COX-2 and iNOS by amentoflavone and quercetin in A549 human lung adenocarcinoma cell line. Prostagl. Leukotr. Essent. Fatty Acids, 2002, 66, 485-492.
68. O'Prey, J.; Brown, J.; Fleming, J.; Harrison, P.R. Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells. Biochem. Pharmacol., 2003, 66, 2075-2088.
69. Che, H.; Lim, H.; Kim, H.P.; Park, H. A chrysin analog exhibited strong inhibitory activities against both PGE2 and NO production. Eur. J. Med. Chem., 2011, 46, 4657-4660.
70. Kawaii, S.; Tomono, Y.; Katase, E.; Ogawa, K.; Yano, M. Antiproliferative activity of flavonoids on several cancer cell lines. Biosci. Biotechnol. Biochem., 1999, 63, 896-899.
71. Cerqueira, F.; Cordeiro-Da-Silva, A.; Araújo, N.; Cidade, H.; Kijjoa, A.; Nascimento, M.S.J. Inhibition of lymphocyte proliferation by prenylated flavones: Artelastin as a potent inhibitor. Life Sci., 2003, 73, 2321-2334.
72. Verbeek, R.; Plomp, A.C.; van Tol, E.A.F.; van Noort, J.M. The flavones luteolin and apigenin inhibit in vitro antigen-specific proliferation and interferon-production by murine and human autoimmune T cells. Biochem. Pharmacol., 2004, 68, 621-629.
73. Zhou, J.R.; Mukherjee, P.; Gugger, E.T.; Tanaka, T.; Blackbum, G.L.; Clinton, S.K. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res., 1998, 58, 5231-5238.
74. Zheng, P.-W.; Chiang, L.-C.; Lin, C.-C. Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci., 2005, 76(12), 1367-1379.
75. Khan, T.H.; Sultana, S. Apigenin induces apoptosis in Hep G2 cells: Possible role of TNF-and IFN-γ. Toxicology, 2006, 217, 206-212.
76. Chiang, L.-C.; Ng, L.T.; Lin, I-C.; Kuo, P.-L.; Lin, C.-C. Anti-proliferative effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer Lett., 2006, 237, 207-214.
77. Raveedran Nair, P.K.; Melnick, S.J.; Wnuk, S.F.; Rapp, M.; Escalon, E.; Ramachandran, C. Isolation and characterization of an anticancer catechol compound from Semecarpus anacardium. J. Ethnopharmacol., 2009, 122, 450-456.
78. Leone, M.; Zhai, D.; Sareth, S.; Kitada, S.; Reed, J.C.; Pellecchia, M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res., 2003, 63, 8118-8121. Comment in: Cancer Res., 2004, 64, 2639; author reply 2640.
79. Kundu, T.; Dey, S.; Roy, M.; Siddiqi, M.; Bhattacharya, R.K. Induction of apoptosis in human leukemia cells by black tea and its polyphenol theaflavin. Cancer Lett., 2005, 230, 111-121.
80. Lahiry, L.; Saha, B.; Chakraborty, J.; Bhattacharyya, S.; Chattopadhyay, S.; Banerjee, S.; Choudhuri, T.; Mandal, D.; Bhattacharyya, A.; Sa, G.; Das, T. Contribution of p53-mediated Bax transactivation in theaflavin-induced mammary epithelial carcinoma cell apoptosis. Apoptosis, 2008, 13, 771-781.
81. Lahiry, L.; Saha, B.; Chakraborty, J; Adhikary, A.; Mohanty, S.; Hossain, D.M.S.; Banerjee, S.; Das, K.; Sa, G.; Das, T. Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis, 2010, 31, 259-268.
82. Stel, A.J.; Cate, B.t.; Jacobs, S.; Kok, J.W.; Spierings, D.C.J.; Dondorff, M.; Helfrich, W.; Kluin-Nelemans, H.C.; de Leij, L.F.M.H.; Withoff, S.; Kroesen, B.J. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J. Immunol., 2007, 178, 2287-2295.
83. Köhler, B.; Anguissola, S.; Concannon, C.G.; Rehm, M.; Kögel, D.; Prehn, J.H.M. Bid participates in genotoxic drug-induced apoptosis of HeLa cells and is essential for death receptor ligands' apoptotic and synergistic effects. PLoS ONE, 2008, 3, e2844.
84. Li, T.; Lu C.; Xia Z.; Xiao B.; Luo, Y. Inhibition of caspase-8 attenuates neuronal death induced by limbic seizures in a cytochrome c-dependent and Smac/DIABLO-independent way. Brain Res., 2006, 1098, 204-211.
85. Basu, A.; Castle, V.P.; Bouzianne, M.; Bhalla, K.; Haldar, S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res., 2006, 66, 4309-4318.
86. Amin, A.R.M.R.; Thakur, V.S.; Paul, R.K.; Feng, G.S.; Qu, C.-K.; Mukhtar, H.; Agarwal, M.L. SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. Proc. Natl. Acad. Sci. USA, 2007, 104, 5419-5424.
87. Hastak, K.; Gupta, S.; Ahmad, N.; Agarwal, M.K.; Agarwal, M.L.; Mukhtar, H. Role of p53 and NF-B in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene, 2003, 22, 4851-4859.
88. Dong, Z.; Ma, W.; Huang, C.; Yang, C.S. Inhibition of tumor promoterinduced activator protein 1 (AP-1) activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res., 1997, 57, 4414-4419.
89. Kandaswami, C.; Lee, L.T.; Lee, P.P.; Hwang, J.J.; Ke, F.C.; Huang, Y.T.; Lee, M.T. The antitumor activities of flavonoids. In Vivo, 2005, 19, 895-909. Erratum in: In Vivo, 2007, 21, 1172. In Vivo, 2007, 21, 553. Kanadaswami, Chithan [corrected to Kandaswami, Chithan].
90. Kuo, M.-L.; Lin, J.-K.; Huang, T.-S.; Yang, N.-C. Reversion of the transformed phenotypes of v-H-ras NIH3T3 cells by flavonoids through attenuating the content of phosphotyrosine. Cancer Lett., 1994, 87, 91-97.
91. Kuo, M.L.; Yang, N.C. Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem. Biophys. Res. Commun., 1995, 212, 767-775.
92. Shin, G.-C.; Kim, C.; Lee, J.-M.; Cho, W.-S.; Lee, S.-G.; Jeong, M.; Cho, J.; Lee, K. Apigenin-induced apoptosis is mediated by reactive oxygen species and activation of ERK1/2 in rheumatoid fibroblast-like synoviocytes. Chem.-Biol. Interact., 2009, 182, 29-36.
93. Mathivadhani, P.; Shanthi, P.; Sachdanandam, P. Effect of Semecarpus anacardium nut extract on ECM and proteases in mammary carcinoma rats. Vascul. Pharmacol., 2007, 46, 419-426.
94. Markovits, J.; Linassier, C.; Fosse, P.; Couprie, J.; Pierre, J.; Jacquemin-Sablon, A.; Saucier, J.M.; Le Pecq, J.B.; Larsen, A.K. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res., 1989, 49, 5111-5117.
95. Agullo, G.; Gamet-Payrastre, L.; Manenti, S.; Viala, C.; Rémésy, C.; Chap, H.; Payrastre, B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem. Pharmacol., 1997, 53, 1649-1657.
96. Lepley, D.M.; Li, B.; Birt, D.F.; Pelling, J.C. The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Carcinogenesis, 1996, 17, 2367-2375.
97. Plaumann, B.; Fritsche, M.; Rimpler, H.; Brandner, G.; Hess, R.D. Flavonoids activate wild-type p53. Oncogene, 1996, 13, 1605-1614.
98. Chen, Z.P.; Schell, J.B.; Ho, C.T.; Chen, K.Y. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett., 1998, 129, 173-179.
99. Vintonyak, V.V.; Antonchick, A.P.; Rauh, D.; Waldmann, H. The therapeutic potential of phosphatase inhibitors. Curr. Opin. Chem. Biol., 2009, 13, 272-283.
100. Kuete, V.; Krusche, B.; Youns, M.; Voukeng, I.; Fankam, A.G.; Tankeo, S.; Lacmata, S.; Efferth, T. Cytotoxicity of some Cameroonian spices and selected medicinal plant extracts. J. Ethnopharmacol., 2011, 134, 803-812.
101. Iwase, H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 2008, 15, 278-290.
102. Altucci, L.; Addeo, R.; Cicatiello, L.; Dauvois, S.; Parker, M.G.; Truss, M.; Beato, M.; Sica, V.; Bresciani, F.; Weisz, A. 17-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogene, 1996, 12, 2315-2324.
103. Mukherjee, S.; Mukherjee, A.; Saha, A. QSAR modeling on binding affinity of diverse estrogenic flavonoids: electronic, topological and spatial functions in quantitative approximation. J. Mol. Struct.: THEOCHEM, 2005, 715, 85-90.
104. Foster, J.S.; Wimalasena, J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol., 1996, 10, 488-498.
105. Moriarty, K.; Kim, K.H.; Bender, J.R. Minireview: estrogen receptormediated rapid signaling. Endocrinology 2006, 147, 5557-5563.
106. Pietras, R.J.; Marquez-Garban, D.C. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin. Cancer Res., 2007, 13, 4672-4676.
107. Arpino, G.; Wiechmann, L.; Osborne, C.K.; Schiff, R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev., 2008, 29, 217-233.
108. Gompel, A.; Somai, S.; Chaouat, M.; Kazem, A.; Kloosterboer, H.J.; Beusman, I.; Forgez, P.; Mimoun, M.; Rostene, W. Hormonal regulation of apoptosis in breast cells and tissues. Steroids, 2000, 65, 593-598.
109. Swaby, R.F.; Jordan, V.C. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin. Breast Cancer 2008, 8, 124-133.
110. Lewis-Wambi, J.S.; Jordan, V.C. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res. 2009, 11, 206-217.
111. Zeitlin, B.D.; Zeitlin, I.J.; Nor, J.E. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J. Clin. Oncol., 2008, 26, 4180-4188.
112. Leone, M.; Zhai, D.; Sareth, S.; Kitada, S.; Reed, J.C.; Pellecchia, M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res., 2003, 63, 8118-8121.
113. Akamatsu, M. Current state and perspectives of 3D-QSAR. Curr. Top. Med. Chem., 2002, 2, 1381-1394.
114. Bradbury, S.P. Predicting modes of toxic action from chemical structure: an overview. SAR QSAR Environ. Res., 1994, 2, 89-104.
115. Galati, G.; Teng, S.; Moridani, M.Y.; Chan, T.S.; O'Brien, P.J. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metabol. Drug Interact., 2000, 17, 311-349.
116. Moridani, M.Y.; Galati, G.; O'Brien, P.J. Comparative quantitative structure toxicity relationships for flavonoids evaluated in isolated rat hepatocytes and HeLa tumor cells. Chem. Biol. Interact., 2002, 139, 251-264.
117. Thakur, A.; Vishwakarma, S.; Thakur, M. QSAR study of flavonoid derivatives as p56lck tyrosinkinase inhibitors. Bioorg. Med. Chem., 2004, 12, 1209-1214.
118. Rackova, L.; Firakova, S.; Kostalova, D.; Stefek, M.; Sturdik, E.; Majekova, M. Oxidation of liposomal membrane suppressed by flavonoids: Quantitative structure-activity relationship. Bioorg. Med. Chem., 2005, 13, 6477-6484.
119. van Zanden, J.J.; Wortelboer, H.M.; Bijlsma, S.; Punt, A.; Usta, M.; van Bladeren, P.J.; Rietjens, I.M.C.M.; Cnubben, N.H.P. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol., 2005, 69, 699-708.
120. Badhan, R.; Penny, J. In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur. J. Med. Chem., 2006, 41, 285-295.
121. Cabrera, M.; Simoens, M.; Falchi, G.; Lavaggi, M.L.; Piro, O.E.; Castellano, E.E.; Vidal, A.; Azqueta, A.; Monge, A.; López de Ceráin, A.; Sagrera, G.; Seoane, G.; Cerecetto, H.; González, M. Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structureactivity relationships. Bioorg. Med. Chem., 2007, 15, 3356-3367.
122. Jha, A.; Mukherjee, C.; Rolle, A.J.; De Clercq, E.; Balzarini, J.; Stables, J.P. Cytostatic activity of novel 4'-aminochalcone-based imides. Bioorg. Med. Chem. Lett., 2007, 17, 4545-4550.
123. Boik, J.C.; Newman, R.A. Structure-activity models of oral clearance, cytotoxicity, and LD50: a screen for promising anticancer compounds. BMC Pharmacol., 2008, 8, 12-24.
124. Zhang, S.X.; Feng, J.; Kuo, S.C.; Brossi, A.; Hamel, E.; Tropsha, A.; Lee, K.H. Antitumor agents. 199. Three-dimensional quantitative structureactivity relationship study of the colchicine binding site ligands using comparative molecular field analysis. J. Med. Chem., 2000, 43, 167-176.
125. Liao, S.Y.; Chen, J.C.; Qian, L.; Shen, Y.; Zheng, K.C. QSAR, action mechanism and molecular design of flavone and isoflavone derivatives with cytotoxicity against HeLa. Eur. J. Med. Chem., 2008, 43, 2159-2170.
126. Liao, S.Y.; Qian, L.; Miao, T.F.; Lu, H.L.; Zheng, K.C. CoMFA and docking studies of 2-phenylindole derivatives with anticancer activity. Eur. J. Med. Chem., 2009, 44, 2822-2827.
127. Karkola, S.; Wähälä, K. The binding of lignans, flavonoids and coumestrol to CYP450 aromatase: A molecular modelling study. Mol. Cell. Endocrinol., 2009, 301, 235-244.
128. Kumar, D.; Kumar, N.M.; Akamatsu, K.; Kusaka, E.; Harada, H.; Ito, T. Synthesis and biological evaluation of indolyl chalcones as antitumor agents. Bioorg. Med. Chem. Lett., 2010, 20, 3916-3919.
129. De-Eknamkul, W; Umehara, K.; Monthakantirat, O.; Toth, R.; Frecer, V.; Knapic, L.; Braiuca, P.; Noguchi, H.; Miertus, S. QSAR study of natural estrogen-like isoflavonoids and diphenolics from Thai medicinal plants. J. Mol. Graph. Model., 2011, 29, 784-794.
130. Cole, S.P.; Bhardwaj, G.; Gerlach, J.H.; Mackie, J.E.; Grant, C.E.; Almquist, K.C.; Stewart, A.J.; Kurz, E.U.; Duncan, A.M.; Deeley, R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 1992, 258, 1650-1654. Erratum in: Science, 1993, 260, 879.
131. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S. A., 1999, 95, 15665-15670.
132. Maliepaard, M.; Scheffer, G.L.; Faneyte, I.F.; van Gastelen, M.A.; Pijnenborg, ACLM; Schinkel, AH; van de Vijver, M.J.; Scheper, R.J.; Schellens, J.H.M. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 2001, 61, 3458-3464.
133. Ishikawa, T.; Nakagawa, H. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J. Exp. Ther. Oncol., 2009, 8, 5-24.
134. Nicolle, E.; Boumendjel, A.; Macalou, S.; Genoux, E.; Ahmed-Belkacem, A.; Carrupt, P.A.; Di Pietro, A. QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv. Drug Deliv. Rev., 2009, 61, 34-46.
135. Zhang, S.; Yang, X.; Coburn, R.A.; Morris, M.E. Structure activity relationships and quantitative structure activity relationships for the flavonoidmediated inhibition of breast cancer resistance protein. Biochem. Pharmacol., 2005, 70, 627-639.
136. Nicolle, E.; Boccard, J.; Guilet, D.; Dijoux-Franca, M.G.; Zelefac, F.; Macalou, S.; Grosselin, J.; Schmidt, J.; Carrupt, P.A.; Di Pietro, A.; Boumendjel, A. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur. J. Pharm. Sci., 2009, 38, 39-46.
137. Boccard, J.; Bajot, F.; Di Pietro, A.; Rudaz, S.; Boumendjel, A.; Nicolle, E.; Carrupt, P.-A. A 3D linear solvation energy model to quantify the affinity of flavonoid derivatives toward P-glycoprotein. Eur. J. Pharm. Sci., 2009, 36, 254-264.
138. Pal, D.; Mitra, A.K. MDR-and CYP3A4-mediated drug-herbal interactions. Life Sci., 2006, 78, 2131-2145.
139. Go, M.L.; Wu, X.; Liu, X.L. Chalcones: An update on cytotoxic and chemopreventive properties. Curr. Med. Chem., 2005, 12, 481-499.
140. Echeverria, C.; Santibañez, J.S.; Donoso-Tauda, O.; Escobar, C.A.; Ramirez-Tagle, R. Structural antitumoral activity relationships of synthetic chalcones. Int. J. Mol. Sci., 2009, 10, 221-231.
141. Katsori, A.M.; Hadjipavlou-Litina, D. Chalcones in cancer: understanding their role in terms of QSAR. Curr. Med. Chem., 2009, 16, 1062-1081.
142. Batovska, D.I.; Todorova, I.T. Trends in utilization of the pharmacological potential of chalcones. Curr. Clin. Pharmacol., 2010, 5, 1-29.
143. Pick, A.; Müller, H.; Mayer, R.; Haenisch, B.; Pajeva, I.K.; Weigt, M.; Bönisch, H.; Müller, C.E.; Wiese, M. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg. Med. Chem., 2011, 19, 2090-2102.
144. Penning, T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr. Rev., 1997, 18, 281-305.
145. Mindnich, R.; Möller, G.; Adamski, J. The role of 17-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol., 2004, 218, 7-20.
146. Lukacik, P.; Kavanagh, K.L.; Oppermann, U. Structure and function of human 17-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol., 2006, 248, 61-71.
147. Brožič, P.; Lanišnik Rižner, T.; Gobec, S. Inhibitors of 17-hydroxysteroid dehydrogenase type 1. Curr. Med. Chem., 2008, 15, 137-150.
148. Poirier, D. Inhibitors of 17-hydroxysteroid dehydrogenases. Curr. Med. Chem., 2003, 10, 453-477.
149. Wuttke, W.; Jarry, H.; Westphalen, S.; Christoffel, V.; Seidlova-Wuttke, D. Phytoestrogens for hormone replacement therapy? J. Steroid Biochem. Mol. Biol., 2002, 83, 133-147.
150. Schweizer, R.A.; Atanasov, A.G.; Frey, B.M.; Odermatt, A. A rapid screening assay for inhibitors of 11-hydroxysteroid dehydrogenases (11-HSD): flavanone selectively inhibits 11-HSD1 reductase activity. Mol. Cell. Endocrinol., 2003, 212, 41-49.
151. Krazeisen, A.; Breitling, R.; Möller, G.; Adamski, J. Human 17-hydroxysteroid dehydrogenase type 5 is inhibited by dietary flavonoids. Adv. Exp. Med. Biol., 2002, 505, 151-161.
152. Le Bail, J.-C.; Pouget, C.; Fagnere, C.; Basly, J.-P.; Chulia, A.-J.; Habrioux, G. Chalcones are potent inhibitors of aromatase and 17-hydroxysteroid dehydrogenase activities. Life Sci., 2001, 68, 751-761.
153. Kristan, K.; Krajnc, K.; Konc, J.; Gobec, S.; Stojan, J.; Lanišnik Rižner, T. Phytoestrogens as inhibitors of fungal 17-hydroxysteroid dehydrogenase. Steroids, 2005, 70, 626-635.
154. Brožič, P.; Golob, B.; Gomboc, N.; Lanišnik Rižner, T.; Gobec, S. Cinnamic acids as new inhibitors of 17-hydroxysteroid dehydrogenase type 5 (AKR1C3). Mol. Cell. Endocrinol., 2006, 248, 233-235.
155. Sova, M.; Perdih, A.; Kotnik, M.; Kristan, K.; Rižner, T.L.; Solmajer, T.; Gobec, S. Flavonoids and cinnamic acid esters as inhibitors of fungal 17-hydroxysteroid dehydrogenase: a synthesis, QSAR and modelling study. Bioorg. Med. Chem., 2006, 14, 7404-7418.
156. Gobec, S.; Sova, M.; Kristan, K.; Lanišnik Rižner, T. Cinnamic acid esters as potent inhibitors of fungal 17-hydroxysteroid dehydrogenase: a model enzyme of the short-chain dehydrogenase/ reductase superfamily. Bioorg. Med. Chem. Lett., 2004, 14, 3933-3936.
157. Brožič, P.; Kocbek, P.; Sova, M.; Kristl, J.; Martens, S.; Adamski, J.; Gobec, S.; Lanišnik Rižner, T. Flavonoids and cinnamic acid derivatives as inhibitors of 17-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol., 2009, 301, 229-234.
158. Bachmann, M.; Moroy, T. The serine/threonine kinase Pim-1. Int. J. Biochem. Cell Biol., 2005, 37, 726-730.
159. Akasaka, H.; Akasaka, T.; Kurata, M.; Ueda, C.; Shimizu, A.; Uchiyama, T.; Ohno, H. Molecular anatomy of BCL6 translocations revealed by longdistance polymerase chain reaction-based assays. Cancer Res., 2000, 60, 2335-2341. Comment in: Cancer Res., 2001, 61, 7363-7364.
160. Pasqualucci, L.; Neumeister, P.; Goossens, T.; Nanjangud, G.; Chaganti, R.S.; Küppers, R.; Dalla-Favera, R. Hypermutation of multiple protooncogenes in B-cell diffuse large-cell lymphomas. Nature, 2001, 412, 341-346.
161. Amson, R; Sigaux, F.; Przedborski, S.; Flandrin, G.; Givol, D.; Telerman, A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 8857-8861.
162. Valdman, A.; Fang, X.; Pang, S.T.; Ekman, P.; Egevad, L. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate, 2004, 60, 367-371.
163. Sperandio Da Silva, G.M.; Sant'Anna, C.M.R.; Barreiro, E.J. A novel 3DQSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. Bioorg. Med. Chem., 2004, 12, 3159-3166.
164. Peng, Y.; Keenan, S.M.; Zhang, Q.; Kholodovych, V.; Welsh, W.J. 3DQSAR Comparative Molecular Field Analysis on opioid receptor antagonists: pooling data from different studies. J. Med. Chem., 2005, 48, 1620-1629.
165. Chen, J.M.; Sheldon, A.; Pincus, M.R. Structure-function correlations of calcium binding and calcium channel activities based on 3-dimensional models of human annexins I, II, III, V and VII. J. Biomol. Struct. Dyn., 1993, 10, 1067-1089.
166. Haji-Momenian, S.; Rieger, J.M.; Macdonald, T.L.; Brown, M.L. Comparative molecular field analysis and QSAR on substrates binding to cytochrome P450 2D6. Bioorg. Med. Chem., 2003, 11, 5545-5554.
167. Ma, X.H.; Zhang, X.Y.; Tan, J.J.; Chen, W.Z.; Wang, C.X. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies. Acta Pharmacol. Sin., 2004, 25, 950-958.
168. Brown, M.L.; Rieger, J.M.; Macdonald, T.L. Comparative molecular field analysis of colchicine inhibition and tubulin polymerization for combretastatins binding to the colchicine binding site on -tubulin. Bioorg. Med. Chem., 2000, 8, 1433-1441.
169. Holder, S.; Lilly, M.; Brown, M.L. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg. Med. Chem., 2007, 15, 6463-6473.
170. Fresco, P.; Borges, F.; Marques, M.P.; Diniz, C. The anticancer properties of dietary polyphenols and its relation with apoptosis. Curr. Pharm Des., 2010, 16, 114-134.
171. Murray, A.W. Recycling the cell cycle: cyclins revisited. Cell, 2004, 116(2), 221-234.
172. Filgueira de Azevedo Jr., W.; Mueller-Dieckmann, H.-J.; Schulze-Gahmen, U.; Worland, P.J.; Sausville, E.; Kim, S.-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 2735-2740.
173. Kim, H.; Lee, E.; Kim, J.; Jung, B.; Chong, Y.; Ahn, J.H.; Lim, Y. A flavonoid gossypin binds to cyclin-dependent kinase 2. Bioorg. Med. Chem. Lett., 2008, 18, 661-664.
174. Chen, S.; Chen, L.; Le, N.T.; Zhao, C.; Sidduri, A.; Lou, J.P.; Michoud, C.; Portland, L.; Jackson, N.; Liu, J.-J.; Konzelmann, F.; Chi, F.; Tovar, C.; Xiang, Q.; Chen, Y.; Wen, Y.; Vassilevet, L.T. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 2134-2138.
175. Arris, C.E.; Boyle, F.T.; Calvert, A.H.; Curtin, N.J.; Endicott, J.A.; Garman, E.F.; Gibson, A.E.; Golding, B.T.; Grant, S.; Griffin, R.J.; Jewsbury, P.; Johnson, L.N.; Lawrie, A.M.; Newell, D.R.; Noble, M.E.M.; Sausville, E.A.; Schultz, R.; Yu, W. Identification of novel purine and pyrimidine cyclindependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem., 2000, 43, 2797-2804.
176. Zhang, L.; Zhu, H.; Wang, Q.; Fang, H.; Xu, W.; Li, M. Homology modeling, molecular dynamic simulation and docking studies of cyclin dependent kinase 1. J. Mol. Model., 2011, 17, 219-226.
177. Ducrot, P.; Legraverend, M.; Grierson, D.S. 3D-QSAR CoMFA on cyclindependent kinase inhibitors. J. Med. Chem., 2000, 43, 4098-4108.
178. Kunick, C.; Lauenroth, K.; Wieking, K.; Xie, X.; Schultz, C.; Gussio, R.; Zaharevitz, D.; Leost, M.; Meijer, L.; Weber, A.; Jørgensen, F.S.; Lemcke, T. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones. J. Med. Chem., 2004, 47, 22-36.
179. Vadivelan, S.; Sinha, B.N.; Irudayam, S.J.; Sarma, A.R.; Jagarlapudi, P. Virtual screening studies to design potent CDK2-cyclin A inhibitors. J. Chem. Inf. Model., 2007, 47, 1526-1535.
180. Lesuisse, D.; Dutruc-Rosset, G.; Tiraboschi, G.; Dreyer, M.K.; Maignan, S.; Chevalier, A.; Halley, F.; Bertrand, P.; Burgevin, M.-C.; Quarteronet, D.; Rooney, T. Rational design of potent GSK3-inhibitors with selectivity for Cdk1 and Cdk2. Bioorg. Med. Chem. Lett., 2010, 20, 1985-1989.
181. Al-Sha'er, M.A.; Taha, M.O. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur. J. Med. Chem., 2010, 45, 4316-4330.
182. Taha, M.O.; Bustanji, Y.; Al-Ghussein, M.A.S.; Mohammad, M.; Zalloum, H.; Al-Masri, I.M.; Atallah, N. Pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening reveal potent glycogen synthase kinase-3-inhibitory activities for cimetidine, hydroxychloroquine and gemifloxacin. J. Med. Chem., 2008, 51, 2062-2077.
183. Abu Khalaf, R.; Abu Sheikha, G.; Bustanji, Y.; Taha, M.O. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration. Eur. J. Med. Chem., 2010, 45, 1598-1617.
184. Al-Nadaf, A.; Abu Sheikha, G.; Taha, M.O. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent -secretase inhibitory leads. Bioorg. Med. Chem., 2010, 18, 3088-3115.
185. Kurogi, Y.; Güner, O.F. Pharmacophore-modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem., 2001, 8, 1035-1055.
186. Poptodorov, K.; Luu, T.; Hoffmann, R. In: Methods and Principles in Medicinal Chemistry, Pharmacophores and Pharmacophores Searches; Langer, T.; Hoffmann, R.D., Eds.; Wiley-VCH: Weinheim, 2006; Vol. 2, pp. 17-47.
187. Lamy, V.; Roussi, S.; Chaabi, M.; Gossé, F.; Lobstein, A.; Raul, F. Lupulone, a hop bitter acid, activates different death pathways involving apoptotic TRAIL-receptors, in human colon tumor cells and in their derived metastatic cells. Apoptosis, 2008, 13, 1232-1242.
188. Zhang, L.; Fang, B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther., 2005, 12, 228-237.
189. Horinaka, M.; Yoshida, T.; Shiraishi, T.; Nakata, S.; Wakada, M.; Nakanishi, R.; Nishino, H.; Sakai, T. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem. Biophys. Res. Commun., 2005, 333, 833-838.
190. Yoshida, T.; Konishi, M.; Horinaka, M.; Yasuda, T.; Goda, A.E.; Taniguchi, H.; Yano, K.; Wakada, M.; Sakai, T. Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem. Biophys. Res. Commun., 2008, 375, 129-133.
191. Szliszka, E.; Czuba, Z.P.; Jernas, K.; Król, W. Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int. J. Mol. Sci., 2008, 9, 56-64.
192. Szliszka, E.; Czuba, Z.P.; Mazur, B.; Sedek, L.; Paradysz, A.; Król, W. Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells. Int. J. Mol. Sci., 2010, 11, 1-13.
193. Szliszka, E.; Czuba, Z.P.; Mertas, A; Paradysz, A.; Król, W. The dietary isoflavone biochanin-A sensitizes prostate cancer cells to TRAIL-induced apoptosis. Urol. Oncol.: Sem. Orig. Invest., 2011, in press, corrected proof. Available online 30 July 2011.
194. Chen, W.; Wang, X.; Zhuang, J.; Zhang, L.; Lin, Y. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAILinduced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis, 2007, 28, 2114-2121.
195. Siegelin, M.D.; Reuss, D.E.; Habel, A.; Rami, A.; von Deimling A. Quercetin promotes degradation of survivin and thereby enhances deathreceptor-mediated apoptosis in glioma cells. Neuro-Oncol., 2009, 11, 122-131.
196. Jacquemin, G.; Granci, V.; Gallouet, A.S.; Lalaoui, N.; Morlé, A.; Iessi, E.; Morizot, A.; Garrido, C.; Guillaudeux, T.; Micheau, O. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematol., 2012, 97, 38-46.
197. Kobayashi, T; Nakata, T; Kuzumaki, T. Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett., 2002, 176, 17-23.
198. West, K.A.; Castillo, S.S.; Dennis, P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat., 2002, 5, 234-248.
199. Bonham, M.; Posakony, J.; Coleman, I.; Montgomery, B.; Simon, J.; Nelson, P.S. Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma. Clin. Cancer Res., 2005, 11, 3905-3914.
200. Gonzalez, C.A.; Riboli, E. Diet and cancer prevention: where we are, where we are going. Nutr. Cancer, 2006, 56, 225-231.
201. Moon, Y.J.; Wang, X.; Morris, M.E. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol. In Vitro, 2006, 20, 187-210.
202. Prasad, S.; Phromnoi, K.; Yadav, V.R.; Chaturvedi, M.M.; Aggarwal, B.B. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med., 2010, 76, 1044-1063.
203. Shu, L.; Cheung, K.L.; Khor, T.O.; Chen, C.; Kong, A.N. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metast. Rev., 2010, 29, 483-502.
204. Morris, M.E.; Zhang, S. Flavonoid-drug interactions: Effects of flavonoids on ABC transporters. Life Sci., 2006, 78, 2116-2130.
205. Adhami, V.M.; Malik, A.; Zaman, N.; Sarfaraz, S.; Siddiqui, I.A.; Syed, D.N.; Afaq, F.; Pasha, F.S.; Saleem M.; Mukhtar H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res., 2007, 13, 1611-1619.
206. Bosetti, C.; Bravi, F.; Talamini, R.; Parpinel, M.; Gnagnarella, P.; Negri, E.; Montella, M.; Lagiou, P.; Franceschi, S.; La Vecchia, C. Flavonoids and prostate cancer risk: a study in Italy. Nutr. Cancer, 2006, 56, 123-127.
207. Bosetti, C.; Rossi, M.; McLaughlin, J.K.; Negri, E.; Talamini, R.; Lagiou, P.; Montella, M.; Ramazzotti, V.; Franceschi, S.; LaVecchia, C. Flavonoids and the risk of renal cell carcinoma. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 98-101.
208. Leitner, H.M.; Kachadourian, R.; Day, B.J. Harnessing drug resistance: Using ABC transporter proteins to target cancer cells. Biochem. Pharmacol., 2007, 74, 1677-1685.
209. Mink, P.J.; Scrafford, C.G.; Barraj, L.M.; Harnack, L.; Hong, C.P.; Nettleton, J.A.; Jacobs, D.R. Jr. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am. J. Clin. Nutr., 2007, 85, 895-909.
210. Plochmann, K.; Korte, G.; Koutsilieri, E.; Richling, E.; Riederer, P.; Rethwilm, A.; Schreier, P.; Scheller, C. Structure-activity relationships of flavonoid-induced cytotoxicity on human leukemia cells. Arch. Biochem. Biophys., 2007, 460, 1-9.
211. Theodoratou, E.; Kyle, J.; Cetnarskyj, R.; Farrington, S.M.; Tenesa, A.; Barnetson, R.; Porteous, M.; Dunlop, M.; Campbell, H. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 684-693.
212. Aravindaram, K.; Yang, N.S. Anti-inflammatory plant natural products for cancer therapy. Planta Med., 2010, 76, 1103-1117.
213. Tan, A.C.; Konczak, I.; Sze, D.M.; Ramzan, I. Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr. Cancer, 2011, 63, 495-505.
214. Čipák, L.; Novotný, L.; Čipá ková, I.; Rauko, P. Differential modulation of cisplatin and doxorubicin efficacies in leukemia cells by flavonoids. Nutr. Res., 2003, 23, 1045-1057.
215. Čipák, L.; Rauko, P.; Miadoková, E.; Čipáková, I.; Novotný, L. Effects of flavonoids on cisplatin-induced apoptosis of HL-60 and L1210 leukemia cells. Leuk. Res., 2003, 27, 65-72.
216. Sharma, H.; Sen, S.; Singh, N. Molecular pathways in the chemosensitization of -cisplatin by quercetin in human head and neck cancer. Cancer Biol. Ther., 2005, 4, 949-955.
217. Jakubowicz-Gil, J.; Langner, E.; Wertel, I.; Piersiak, T.; Rzeski, W. Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. Chem.-Biol. Interact., 2010, 188, 190-203.
218. Luo, H.; Daddysman, M.K.; Rankin, G.O.; Jiang, B.-H.; Chen, Y.C. Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Cancer Cell Int., 2010, 10, 16.
219. Seoane, J.; Le, H.V.; Massagué, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature, 2002, 419, 729-734.
220. Luo, H.; Jiang, B.; King, S.M.; Chen, Y.C. Inhibition of Cell Growth and VEGF Expression in Ovarian Cancer Cells by Flavonoids. Nutr. Cancer, 2008, 60, 800-809.
221. Zhou, S.F.; Wang, L.L.; Di, Y.M.; Xue, C.C.; Duan, W.; Li, C.G.; Li, Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem., 2008, 15, 1987-2039.
222. Shi, R., Huang, Q., Zhu, X., Ong, Y.B., Zhao, B., Lu, J., Ong, C.N., Shen, H.M. Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol. Cancer Ther., 2007, 6, 1338-1347.
223. Lin, Y.; Shi, R.; Wang, X.; Shen, H.M. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr. Cancer Drug Targets, 2008, 8, 634-646.
224. López-Lázaro, M. Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem., 2009, 9, 31-59.
225. Khoshyomn, S.; Manske, G.C.; Lew, S.M.; Wald, S.L.; Penar, P.L. Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells. Pediatr. Neurosurg., 2000, 33, 123-131.
226. Hwang, J.-T.; Ha, J.; Park, O.J. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem. Biophys. Res. Commun., 2005, 332, 433-440.
227. Lee, S.H.; Ryu, J.K.; Lee, K.-Y.; Woo, S.M.; Park, J.K.; Yoo, J.W.; Kim, Y.-T.; Yoon, Y.B. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett., 2008, 259, 39-49.
228. Siddique, Y.H.; Beg, T.; Afzal, M. Antigenotoxic effect of apigenin against anti-cancerous drugs. Toxicol. In Vitro, 2008, 22, 625-631.
229. Tolomeo, M.; Grimaudo, S.; Di Cristina, A.; Pipitone, R.M.; Dusonchet, L.; Meli, M.; Crosta, L.; Gebbia, N.; Invidiata, F.P.; Titone, L.; Simoni, D. Galangin increases the cytotoxic activity of imatinib mesylate in imatinibsensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. Cancer Lett., 2008, 265, 289-297.
230. Nagaprashantha, L.D.; Vatsyayan, R.; Singhal, J.; Fast, S.; Roby, R.; Awasthi, S.; Singhal, S.S. Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer Biochem. Pharmacol., 2011, 82, 1100-1109.
231. Eddy, S.F.; Kane, S.E.; Sonenshein, G.E. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate. Cancer Res., 2007, 67, 9018-9023.
232. Joshi, S.S.; Kuszynski, C.A.; Bagchi, M.; Bagchi, D. Chemopreventive effects of grape seed proanthocyanidin extract on Chang liver cells. Toxicology, 2000, 155, 83-90.
233. Alves de Rezende, A.A.; Graf, U.; da Rosa Guterres, Z.; Kerr, W.E.; Spanó, M.A. Protective effects of proanthocyanidins of grape (Vitis vinifera L.) seeds on DNA damage induced by doxorubicin in somatic cells of Drosophila melanogaster. Food Chem. Toxicol., 2009, 47, 1466-1472.
234. Giacomelli, S.; Gallo, D.; Apollonio, P.; Ferlini, C.; Distefano, M.; Morazzoni, P.; Riva, A.; Bombardelli, E.; Mancuso, S.; Scambia, G. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci., 2002, 70, 1447-1459.
235. Tyagi, A.K.; Singh, R.P.; Agarwal, C.; Chan, D.C.; Agarwal, R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicininduced growth Inhibition, G2-M arrest, and apoptosis. Clin. Cancer Res., 2002, 8, 3512-3519. Comment in: Di Paola, R.S. To arrest or not to G2-M cell-cycle arrest. Clin. Cancer Res., 2002, 8, 3311-3314.
236. Tyagi, A.K.; Agarwal, C.; Chan, D.C.; Agarwal, R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol. Rep., 2004, 11, 493-499.
237. Li, L.; Zeng, J.; Gao, Y.; He, D. Targeting silibinin in the antiproliferative pathway. Expert Opin. Investig. Drugs, 2010, 19, 243-255.
238. Benavente-García, O.; Castillo, J.; Alcaraz, M.; Vicente, V.; Del Río, J.A.; Ortuño, A. Beneficial action of Citrus flavonoids on multiple cancer-related biological pathways. Curr. Cancer Drug Targets, 2007, 7, 795-809.
239. Benavente-García, O.; Castillo, J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and antiinflammatory activity. J. Agric. Food. Chem., 2008, 56, 6185-6205.
240. Choi, S.Y.; Ko, H.C.; Ko, S.Y.; Hwang, J.H.; Park, J.G.; Kang, S.H.; Han, S.H.; Yun, S.H.; Kim, S.J. Correlation between flavonoid content and the NO production inhibitory activity of peel extracts from various citrus fruits. Biol. Pharm. Bull., 2007, 30, 772-778.
241. Zielińska-Przyjemska, M.; Ignatowicz, E. Citrus fruit flavonoids influence on neutrophil apoptosis and oxidative metabolism. Phytother. Res., 2008, 22, 1557-1562.
242. Meiyanto, E.; Hermawan, A.; Junedi, S.; Fitriasari, A.; Susidarti, R.A. Nobiletin increased cytotoxic activity of doxorubicin on Mcf-7 Cells but not on T47d cells. Int. J. Phytomedicine, 2011, 3, 129-137.
243. Meiyanto, E.; Hermawan, A.; Anindyajati. Natural products for cancertargeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac. J. Cancer Prev., 2012, 13, 427-36.
244. West, K.A.; Castillo, S.S.; Dennis, P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updates, 2002, 5, 234-248.
245. Aung, H.H.; Dey, L.; Mehendale, S.; Xie, J.T.; Wu, J.A.; Yuan, C.S. Scutellaria baicalensis extract decreases cisplatin-induced pica in rats. Cancer Chemother. Pharmacol., 2003, 52, 453-458.
246. Oh, W.K.; Kantoff, P.W.; Weinberg, V.; Jones, G.; Rini, B.I.; Derynck, M.K.; Bok, R.; Smith, M.R.; Bubley, G.J.; Rosen, R.T.; DiPaola, R.S.; Small, E.J. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgenindependent prostate cancer. J. Clin. Oncol., 2004, 22, 3705-3712.
247. Lee, S.W.; Song, G.S.; Kwon, C.H.; Kim, Y.K. Beneficial effect of flavonoid baicalein in cisplatin-induced cell death of human glioma cells. Neurosci. Lett., 2005, 382, 71-75.
248. Momota, H.; Nerio, E.; Holland, E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res., 2005, 65, 7429-7435.
249. Sturla, L.M.; Cowan, C.W.; Guenther, L.; Castellino, R.C.; Kim, J.Y.; Pomeroy, S.L. A novel role for -extracellular signal-regulated kinase 5 and myocyte enhancer factor 2 in medulloblastoma cell death. Cancer Res., 2005, 65, 5683-5689.
250. Scheck, A.C.; Perry, K.; Hank, N.C.; Clark, W.D. Human malignant brain tumor cells. BMC Complement. Altern. Med., 2006, 6, 27.
251. Padmavathi, R.; Senthilnathan, P.; Sakthisekaran, D. Therapeutic effect of propolis and paclitaxel on hepatic phase I and II enzymes and marker enzymes in dimethylbenz(a)anthracene-induced breast cancer in female rats. Comp. Biochem. Physiol. C Toxicol. Pharmacol., 2006, 143, 349-354.
252. Oršolić, N.;Benković, V.;Lisičić, D.; Dikić, D.; Erhard,t J.; Horvat Kneževic, A. Protective effects of propolis and related polyphenolic/ flavonoid compounds against toxicity induced by irinotecan. Med. Oncol., 2010, 27, 1346-1358.
253. Grant, S.; Roberts, J.D. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist.Updates, 2003, 6, 15-26.
254. Granados-Principal, S.; Quiles, J.L.; Ramirez-Tortosa, C.L.; Sanchez-Rovira, P.; Ramirez-Tortosa, M.C. New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem. Toxicology, 2010, 48, 1425-1438.
255. Quiles, J.L.; Huertas, J.R.; Battino, M.; Mataix, J.; Ramírez-Tortosa, M.C. Antioxidant nutrients and adriamycin toxicity. Toxicology, 2002, 180, 79-95.
256. Yang, W.; Ahmed, M.; Tasawwar, B.; Levchenko, T.; Sawant, R.R.; Torchilin, V.; Goldberg, S.N. Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: Reduced tumor growth and increased animal endpoint survival in a small animal tumor model. J. Control. Release, 2012, 160, 239-244.
257. Brechbuhl, H.M.; Kachadourian, R.; Min, E.; Chan, D.; Day, B.J. Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: The role of glutathione. Toxicol. Appl. Pharmacol., 2012, 258, 1-9.
258. Gutierrez-Merino, C.; Lopez-Sanchez, C.; Lagoa, R.; Samhan-Arias, A.K.; Bueno, C.; Garcia-Martinez, V. Neuroprotective actions of flavonoids. Curr. Med. Chem., 2011, 18, 1195-1212.
259. Hwang, S.L.; Shih, P.H.; Yen, G.C. Neuroprotective effects of citrus flavonoids. J. Agric. Food Chem., 2012, 60, 877-885.
260. Russo, M.; Spagnuolo, C.; Tedesco, I.; Bilotto, S.; Russo, G.L. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochem. Pharmacol., 2012, 83, 6-15.
261. Nambiar, D.; Rajamani, P.; Singh, R.P. Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy. Mutat. Res-Rev. Mutat. Res., 2011, 728, 139-157.